PMID- 30146732
OWN - NLM
STAT- MEDLINE
DCOM- 20190227
LR  - 20190227
IS  - 1476-5829 (Electronic)
IS  - 1476-5810 (Linking)
VI  - 17
IP  - 1
DP  - 2019 Mar
TI  - Canine intranasal tumours treated with alternating carboplatin and doxorubin in 
      conjunction with oral piroxicam: 29 cases.
PG  - 42-48
LID - 10.1111/vco.12443 [doi]
AB  - Few veterinary studies have evaluated the response to chemotherapy treatment of 
      canine intranasal tumours, while many have focused on the efficacy of radiation 
      therapy. Given the higher costs and limited access to radiation therapy, 
      alternative treatment options are needed. The study describes a cohort of dogs 
      with histologically confirmed intranasal tumours treated with chemotherapy as a 
      sole therapy. This retrospective study was conducted using data from the 
      Melbourne Veterinary Specialist Centre (MVSC) database between 2004 and 2017. 
      Dogs with a histologically confirmed intranasal tumour who received chemotherapy 
      treatment were included. Signalment, presenting signs, tumour type, chemotherapy 
      details, adverse events (AEs) and survival times were reviewed. Twenty-nine dogs 
      met the inclusion criteria. Overall median survival time for dogs in the study 
      was 234 days (range 12-1698 days). Median survival for dogs with adenocarcinoma 
      or carcinoma (n = 12) was 280 days, transitional cell carcinoma (n = 6) 163 days, 
      squamous cell carcinoma, anaplastic carcinoma or undifferentiated carcinoma (n = 
      7) 59 days and all sarcomas (n = 4) 448 days. Adverse events were reported 
      following 28% of treatments and 69% of dogs experienced at least one AE. Twenty 
      four per cent of all dogs experienced grade 3 or 4 toxicities. The chemotherapy 
      protocol was generally well tolerated. The study suggests potential benefit in 
      the use of chemotherapy for dogs with adenocarcinoma, carcinoma and sarcoma.
CI  - (c) 2018 John Wiley & Sons Ltd.
FAU - Woodruff, Matthew J
AU  - Woodruff MJ
AUID- ORCID: 0000-0003-2599-1931
AD  - Department of Medicine, Melbourne Veterinary Specialist Centre (MVSC), Melbourne, 
      Victoria, Australia.
AD  - Department of Medicine, Adelaide Animal Emergency and Referral Centre, Adelaide, 
      South Australia, Australia.
FAU - Heading, Kathryn L
AU  - Heading KL
AD  - Department of Medicine, Melbourne Veterinary Specialist Centre (MVSC), Melbourne, 
      Victoria, Australia.
FAU - Bennett, Peter
AU  - Bennett P
AD  - Sydney School of Veterinary Science, Faculty of Science, University of Sydney, 
      Sydney, New South Wales, Australia.
LA  - eng
PT  - Journal Article
DEP - 20181219
PL  - England
TA  - Vet Comp Oncol
JT  - Veterinary and comparative oncology
JID - 101185242
RN  - 0 (Antineoplastic Agents)
RN  - 13T4O6VMAM (Piroxicam)
RN  - 80168379AG (Doxorubicin)
RN  - BG3F62OND5 (Carboplatin)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/administration & dosage/*therapeutic use
MH  - Carboplatin/administration & dosage/*therapeutic use
MH  - Dog Diseases/*drug therapy
MH  - Dogs
MH  - Doxorubicin/administration & dosage/*therapeutic use
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Female
MH  - Male
MH  - Nose Neoplasms/*veterinary
MH  - Piroxicam/*therapeutic use
MH  - Retrospective Studies
OTO - NOTNLM
OT  - canine
OT  - chemotherapy
OT  - dog
OT  - intranasal
OT  - toxicity
OT  - tumour
EDAT- 2018/08/28 06:00
MHDA- 2019/02/28 06:00
CRDT- 2018/08/28 06:00
PHST- 2018/03/15 00:00 [received]
PHST- 2018/08/16 00:00 [revised]
PHST- 2018/08/16 00:00 [accepted]
PHST- 2018/08/28 06:00 [pubmed]
PHST- 2019/02/28 06:00 [medline]
PHST- 2018/08/28 06:00 [entrez]
AID - 10.1111/vco.12443 [doi]
PST - ppublish
SO  - Vet Comp Oncol. 2019 Mar;17(1):42-48. doi: 10.1111/vco.12443. Epub 2018 Dec 19.